FDA Filing expected this Q3 for NASDAQ Company’s JW-100 treatment for Eczema; Jupiter Wellness, Inc. (NASDAQ: JUPW)

JUPW Acquisition Reported $28 Million Revenue for 2020
? Developer of CBD Treatments for the Multi-Billion Dollar Skin Care Market.
? Multiple Clinical Studies Underway on Company?s Proprietary Products.
? LOI Signed to Acquire Company and its Affiliates with Over 300 SKUs.
? Highly Qualified Management with Extensive Accomplishments in Place.

? Investment in Theme Park Business Sees Surge in Recent Business as the Pandemic Declines.
Jupiter Wellness, Inc. (NASDAQ: JUPW) is a leading developer of Herbal based medical therapeutics and wellness products. The JUPW clinical pipeline of prescription enhanced skin care therapeutics address indications including eczema, burns, herpes cold sores, and skin cancer. JUPW generates revenues from a growing line of proprietary over-the-counter skincare products including its flagship CaniSun? sunscreen and other wellness brands sold through its robust distribution platform.
JUPW is NASDAQ listed and has an attractive share structure with only
11,410,188 shares currently outstanding.

? JUPW Advances Clinical Pipeline of Topical Treatments

On April 29th JUPW announced an update on its clinical pipeline of Herbal based therapeutic topical formulations including JW-100 for the treatment of eczema, JW-200 for skin cancer, JW-300 for burns, and JW-400 for herpes cold sores.

Commenced Patient Enrollment for Skin Cancer: Study Completion Expected Q4 2021

The JUPW JW-200 is designed to provide action and relief in the treatment of Actinic Keratosis (AK), the most common precancer that forms on skin as a result of exposure to ultraviolet (UV) rays. The objective of this double blinded, placebo-controlled study is to evaluate the efficacy of JW-200 in both the treatment and prevention of disease, with a primary efficacy endpoint of the percentage of patients with complete clearance of AK lesions. An estimated 120 adults diagnosed with AK will be recruited, with an expected study completion date of Q4 2021.

Patient Recruitment Started for First Degree Burns: Topline Data Expected Q4 2021
The JUPW JW-300 is being evaluated in a clinical study for the treatment of first-degree burns resulting from sun exposure. The double blinded, placebo-controlled trial is recruiting an estimated 44 patients who have first degree burns induced by UVB irradiation. The primary endpoint is the reduction in erythema within 24 hours of treatment. The trial is expected to be completed in Q3 2021, with topline data expected Q4 2021.

The global eczema market is valued at $10 billion and is expected to grow at a CAGR of 13% through 2025. Ten percent of the U.S. population, or 31.6 million people, have eczema, and according to NationalEczema.org, 86% of people are not satisfied with their current treatment.

JW-400 for Treatment of Herpes Cold Sores Expected to Commence Recruitment Q4 2021
The double blind, placebo controlled JUPW study is now preparing for recruitment of 40 patients with recurrent herpes labialis infection (HSV) who had their initial infection more than one year prior. The primary endpoint is the duration of the herpes labialis episode. The herpes simplex virus treatment market was $4.8 billion in 2017. Nearly half of Americans age14-29 have HSV-1, known as the cold sore virus.
? JUPW Enters into Letter of Intent to Acquire JustCBD and its Affiliates

On April 20th JUPW announced it has signed a non-binding Letter of Intent with JustCBD and its affiliates to purchase 51% of JustCBD for $30 million in cash. Per the Letter of Intent, JustCBD would also receive a put option to sell, at its sole discretion, the remaining 49% of JustCBD to JUPW for an additional $30 million in a combination of JUPW common stock (not to exceed 25% of the outstanding shares of JUPW) and preferred shares, both valued at $5.00 per share.

? JUPW to Support Growth in CBD-Based Pharma & Consumer Products

On April 16th JUPW announced it has appointed Dr. Glynn Wilson as Chief Science Officer, Rich Miller as Chief Compliance Officer, and Ryan Allison as Chief Operating Officer. Over the past quarters, JUPW has grown its CBD-based consumer wellness business to include 40 products across seven brands in six categories, while also advancing its clinical pipeline with three indications in Phase 1 equivalent studies and one indication ready for an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) based on a successful Phase 1 equivalent which met its primary endpoint.
Rich Miller continues to serve as a Director for JUPW and now moves into the newly created position of Chief Compliance Officer overseeing regulatory affairs for securities, CBD-based products, JUPW subsidiaries, manufacturing, and international trade. As JUPW expands through both organic growth and acquisition, Mr. Miller serves a critical role in assuring the Company defines best practices in innovation as a leader in its industry segments.

For additional information on Jupiter Wellness, Inc. (JUPW) visit http://www.jupiterwellnessinc.com/

User :- Phillip Fleck

Email :-ficket027@gmail.com